China Pharma Holdings, Inc. (CPHI)
USD 1.63
(5.2%)
USD 1.63
(5.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.07 Million USD | 69.88% |
| 2022 | -10.22 Million USD | -159.34% |
| 2021 | -3.94 Million USD | -24.69% |
| 2020 | -3.16 Million USD | 84.96% |
| 2019 | -21.02 Million USD | -95.57% |
| 2018 | -10.75 Million USD | 44.23% |
| 2017 | -19.27 Million USD | -109.94% |
| 2016 | -9.18 Million USD | 40.39% |
| 2015 | -15.4 Million USD | 40.86% |
| 2014 | -26.04 Million USD | -30.18% |
| 2013 | -20 Million USD | -533.29% |
| 2012 | 4.61 Million USD | -76.04% |
| 2011 | 19.26 Million USD | -17.7% |
| 2010 | 23.41 Million USD | 15.72% |
| 2009 | 20.23 Million USD | 13.45% |
| 2008 | 17.83 Million USD | 39.11% |
| 2007 | 12.81 Million USD | 49.29% |
| 2006 | 8.58 Million USD | 126.0% |
| 2005 | 3.79 Million USD | 853.44% |
| 2004 | -504.29 Thousand USD | -122.78% |
| 2003 | -226.36 Thousand USD | 79.5% |
| 2002 | -1.1 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -955.89 Thousand USD | 22.42% |
| 2024 Q2 | -1.43 Million USD | -50.45% |
| 2023 Q2 | -593.02 Thousand USD | 70.24% |
| 2023 FY | -3.07 Million USD | 69.88% |
| 2023 Q1 | -1.99 Million USD | -47.84% |
| 2023 Q3 | -777.6 Thousand USD | -31.12% |
| 2023 Q4 | -1.23 Million USD | -58.46% |
| 2022 Q2 | -2.47 Million USD | 8.16% |
| 2022 Q3 | -790.77 Thousand USD | 68.02% |
| 2022 FY | -10.22 Million USD | -159.34% |
| 2022 Q1 | -2.69 Million USD | 12.2% |
| 2022 Q4 | -1.34 Million USD | -70.45% |
| 2021 FY | -3.94 Million USD | -24.69% |
| 2021 Q1 | -767.32 Thousand USD | 36.53% |
| 2021 Q2 | -824.76 Thousand USD | -7.48% |
| 2021 Q3 | -826.66 Thousand USD | -0.23% |
| 2021 Q4 | -3.06 Million USD | -270.91% |
| 2020 Q1 | -660.89 Thousand USD | 96.47% |
| 2020 FY | -3.16 Million USD | 84.96% |
| 2020 Q3 | -1 Million USD | -7836.88% |
| 2020 Q2 | 13.05 Thousand USD | 101.98% |
| 2020 Q4 | -1.2 Million USD | -19.72% |
| 2019 Q1 | -417.73 Thousand USD | 94.5% |
| 2019 FY | -21.02 Million USD | -95.57% |
| 2019 Q3 | -700.95 Thousand USD | 16.36% |
| 2019 Q2 | -838.1 Thousand USD | -100.63% |
| 2019 Q4 | -18.74 Million USD | -2574.25% |
| 2018 FY | -10.75 Million USD | 44.23% |
| 2018 Q4 | -7.59 Million USD | -308.94% |
| 2018 Q3 | -1.85 Million USD | -84.17% |
| 2018 Q2 | -1 Million USD | -243.48% |
| 2018 Q1 | -293.48 Thousand USD | 97.88% |
| 2017 Q2 | -2.28 Million USD | -136.62% |
| 2017 Q3 | -2.19 Million USD | 4.04% |
| 2017 Q4 | -13.82 Million USD | -529.82% |
| 2017 FY | -19.27 Million USD | -109.94% |
| 2017 Q1 | -966.89 Thousand USD | 71.78% |
| 2016 Q4 | -3.42 Million USD | -95.78% |
| 2016 FY | -9.18 Million USD | 40.39% |
| 2016 Q1 | -1.55 Million USD | -286.53% |
| 2016 Q2 | -2.45 Million USD | -58.01% |
| 2016 Q3 | -1.74 Million USD | 28.69% |
| 2015 Q4 | 832.51 Thousand USD | -71.6% |
| 2015 Q2 | -4.11 Million USD | 48.39% |
| 2015 Q1 | -7.97 Million USD | 8.2% |
| 2015 FY | -15.4 Million USD | 40.86% |
| 2015 Q3 | 2.93 Million USD | 171.24% |
| 2014 Q1 | -2.39 Million USD | 77.08% |
| 2014 Q2 | -8.64 Million USD | -261.56% |
| 2014 Q3 | -6.32 Million USD | 26.79% |
| 2014 Q4 | -8.68 Million USD | -37.27% |
| 2014 FY | -26.04 Million USD | -30.18% |
| 2013 Q1 | -2.81 Million USD | -126.05% |
| 2013 Q2 | -4.46 Million USD | -58.72% |
| 2013 Q3 | -2.3 Million USD | 48.43% |
| 2013 Q4 | -10.42 Million USD | -353.07% |
| 2013 FY | -20 Million USD | -533.29% |
| 2012 Q4 | -1.24 Million USD | -196.03% |
| 2012 FY | 4.61 Million USD | -76.04% |
| 2012 Q3 | 1.29 Million USD | -26.39% |
| 2012 Q2 | 1.75 Million USD | -37.29% |
| 2012 Q1 | 2.8 Million USD | -51.66% |
| 2011 FY | 19.26 Million USD | -17.7% |
| 2011 Q4 | 5.8 Million USD | 76.35% |
| 2011 Q3 | 3.29 Million USD | -35.06% |
| 2011 Q2 | 5.06 Million USD | -0.68% |
| 2011 Q1 | 5.1 Million USD | -38.94% |
| 2010 Q4 | 8.35 Million USD | 41.32% |
| 2010 Q3 | 5.91 Million USD | -2.77% |
| 2010 FY | 23.41 Million USD | 15.72% |
| 2010 Q2 | 6.08 Million USD | 25.35% |
| 2010 Q1 | 4.85 Million USD | -4.95% |
| 2009 Q2 | 4.28 Million USD | 16.55% |
| 2009 FY | 20.23 Million USD | 13.45% |
| 2009 Q4 | 5.1 Million USD | -28.72% |
| 2009 Q3 | 7.16 Million USD | 67.13% |
| 2009 Q1 | 3.67 Million USD | -31.31% |
| 2008 Q2 | 4.03 Million USD | -3.66% |
| 2008 Q4 | 5.35 Million USD | 25.94% |
| 2008 FY | 17.83 Million USD | 39.11% |
| 2008 Q3 | 4.25 Million USD | 5.31% |
| 2008 Q1 | 4.19 Million USD | 3.87% |
| 2007 FY | 12.81 Million USD | 49.29% |
| 2007 Q4 | 4.03 Million USD | 30.79% |
| 2007 Q1 | 2.37 Million USD | -31.75% |
| 2007 Q2 | 3.32 Million USD | 40.1% |
| 2007 Q3 | 3.08 Million USD | -7.26% |
| 2006 Q2 | 1.83 Million USD | 13.07% |
| 2006 Q1 | 1.61 Million USD | 0.0% |
| 2006 Q3 | 1.7 Million USD | -6.75% |
| 2006 Q4 | 3.47 Million USD | 103.79% |
| 2006 FY | 8.58 Million USD | 126.0% |
| 2005 Q2 | -1.77 Million USD | -4885.2% |
| 2005 FY | 3.79 Million USD | 853.44% |
| 2005 Q1 | -35.67 Thousand USD | -105.55% |
| 2005 Q3 | 510.41 Thousand USD | 128.7% |
| 2004 Q3 | -10.72 Thousand USD | 89.08% |
| 2004 Q4 | -17.35 Thousand USD | -61.85% |
| 2004 FY | -504.29 Thousand USD | -122.78% |
| 2004 Q2 | -98.17 Thousand USD | -2903.31% |
| 2004 Q1 | 3502.00 USD | 722.02% |
| 2003 Q4 | -563.00 USD | 99.86% |
| 2003 Q2 | -40.64 Thousand USD | 50.18% |
| 2003 Q1 | -81.57 Thousand USD | 21.25% |
| 2003 Q3 | -409.06 Thousand USD | -906.47% |
| 2003 FY | -226.36 Thousand USD | 79.5% |
| 2002 FY | -1.1 Million USD | 0.0% |
| 2002 Q4 | -103.59 Thousand USD | -40567.97% |
| 2002 Q3 | 256.00 USD | 100.05% |
| 2002 Q2 | -474.44 Thousand USD | -32.01% |
| 2002 Q1 | -359.4 Thousand USD | -261.56% |
| 2001 Q4 | -99.4 Thousand USD | 41.83% |
| 2001 Q3 | -170.87 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| cbdMD, Inc. | -22.93 Million USD | 86.578% |
| cbdMD, Inc. | -22.93 Million USD | 86.578% |
| Zomedica Corp. | -34.52 Million USD | 91.083% |